Cargando…

Abatacept and tocilizumab tapering in rheumatoid arthritis patients: results of SONATA—a retrospective, exploratory cohort study

OBJECTIVES: As data on disease-activity-guided dose optimization of abatacept and tocilizumab are scarce, we explored the feasibility, effectiveness and safety of dose optimization of these biological DMARDs in RA patients in daily practice. METHODS: RA patients who had been treated with abatacept o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bouman, Chantal A M, Tweehuysen, Lieke, Haverkort, Dieneke, van den Ende, Cornelia H, van der Maas, Aatke, den Broeder, Alfons A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649917/ https://www.ncbi.nlm.nih.gov/pubmed/31431957 http://dx.doi.org/10.1093/rap/rky008

Ejemplares similares

What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?
por: Bouman, Chantal A M, et al.
Publicado: (2017)

Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis
por: Tweehuysen, Lieke, et al.
Publicado: (2018)

Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review
por: Tweehuysen, Lieke, et al.
Publicado: (2017)

bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search
por: Verhoef, Lise M., et al.
Publicado: (2017)

PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial
por: Marsman, Diane E., et al.
Publicado: (2022)

(Dis)agreement of polymyalgia rheumatica relapse criteria, and prediction of relapse in a retrospective cohort
por: Bolhuis, Thomas E., et al.
Publicado: (2022)

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
por: van der Maas, Aatke, et al.
Publicado: (2012)

Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study
por: den Broeder, Alfons A, et al.
Publicado: (2013)

Extra-articular findings with FDG-PET/CT in rheumatoid arthritis patients: more harm than benefit
por: Ulijn, Evy, et al.
Publicado: (2022)

Genetic variant in IL-32 is associated with the ex vivo cytokine production of anti-TNF treated PBMCs from rheumatoid arthritis patients
por: Damen, Michelle S. M. A., et al.
Publicado: (2018)

Perceived need to take medication is associated with medication non-adherence in patients with rheumatoid arthritis
por: Zwikker, Hanneke E, et al.
Publicado: (2014)

Comparing the effectiveness and safety of Abatacept and Tocilizumab in elderly patients with rheumatoid arthritis
por: Temmoku, Jumpei, et al.
Publicado: (2022)

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial
por: van Herwaarden, Noortje, et al.
Publicado: (2015)

The Dutch Lower Extremity Functional Scale was highly reliable, valid and responsive in individuals with hip/knee osteoarthritis: a validation study
por: Hoogeboom, Thomas J, et al.
Publicado: (2012)

Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates
por: Diep, Laetitia, et al.
Publicado: (2022)

Prediction Aided Tapering In rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial
por: Messelink, Marianne A., et al.
Publicado: (2022)

Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial
por: Michielsens, Celia A. J., et al.
Publicado: (2020)

Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis
por: Crnkic Kapetanovic, Meliha, et al.
Publicado: (2013)

Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
por: Takahashi, Nobunori, et al.
Publicado: (2013)

(Ultra-)low dosing of rituximab in rheumatoid arthritis: chances and challenges
por: den Broeder, Alfons A, et al.
Publicado: (2021)

Tocilizumab and Abatacept for the Treatment of Childhood Chronic Uveitis: A Monocentric Comparison Experience
por: Maccora, Ilaria, et al.
Publicado: (2022)

Non-pharmacological care for patients with generalized osteoarthritis: design of a randomized clinical trial
por: Hoogeboom, Thomas J, et al.
Publicado: (2010)

Feasibility and potential effectiveness of a non-pharmacological multidisciplinary care programme for persons with generalised osteoarthritis: a randomised, multiple-baseline single-case study
por: Hoogeboom, Thomas J, et al.
Publicado: (2012)

Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2016)

Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis
por: Huoponen, Saara, et al.
Publicado: (2019)

Transcriptomic profile comparison of monocytes from rheumatoid arthritis patients in treatment with methotrexate, anti-TNFa, abatacept or tocilizumab
por: Talmon, Maria, et al.
Publicado: (2023)

Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies
por: Hirabara, Shinya, et al.
Publicado: (2014)

The balance between Foxp3 and Ror-γt expression in peripheral blood is altered by tocilizumab and abatacept in patients with rheumatoid arthritis
por: Tada, Yoshifumi, et al.
Publicado: (2016)

Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis
por: Suzuki, Takako, et al.
Publicado: (2018)

Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
por: Gottenberg, Jacques-Eric, et al.
Publicado: (2019)

Tocilizumab Attenuates Anti-neutrophil Cytoplasmic Antibody-associated Nephritis Occurring during Abatacept and Adalimumab Therapy for Rheumatoid Arthritis
por: Yoshimura, Yusuke, et al.
Publicado: (2022)

Using real-world data to dynamically predict flares during tapering of biological DMARDs in rheumatoid arthritis: development, validation, and potential impact of prediction-aided decisions
por: van der Leeuw, Matthijs S., et al.
Publicado: (2022)

Practice what you preach? An exploratory multilevel study on rheumatoid arthritis guideline adherence by rheumatologists
por: Lesuis, N, et al.
Publicado: (2016)

Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008)

Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006)

Abatacept treatment for rheumatoid arthritis
por: Schiff, Michael
Publicado: (2011)

Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study)
por: van der Togt, Céleste J.T., et al.
Publicado: (2022)

Humoral response to coronavirus disease-19 vaccines is dependent on dosage and timing of rituximab in patients with rheumatoid arthritis
por: van der Togt, Céleste J T, et al.
Publicado: (2022)

Seroconversion after a third COVID-19 vaccine is affected by rituximab dose but persistence is not in patients with rheumatoid arthritis
por: van der Togt, Céleste J T, et al.
Publicado: (2022)

Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial
por: den Broeder, Alfons A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ghol25s6n0smva7sj1s50hohgl